3. ARTHRITISArthritis is refers to more than 100 types rheumatic conditions, both inflammatory and non-inflammatory, affecting joints as well as surrounding structures and other tissues. Many of them are systemic diseases that can cause generalized problems and fatigue with the heart, lungs, skin, kidneys and other parts of the body [17]. There are over 100 different forms of arthritis. The most common form, osteoarthritis, is a result of trauma to the joint, infection of the joint, or age. Other arthritis forms are Rheumatoid arthritis (RA) [18]. The major complaint by individuals who have arthritis is joint pain. Pain is often a constant and may be localized to the affected joint. The pain from arthritis is due to inflammation that occurs around the joint, damage to the joint from disease, daily wear and tear of joint, muscle strains caused by forceful movements against stiff painful joints and fatigue [19]. The common types of arthritis and related conditions: Osteoarthritis (OA), Rheumatoid Arthritis (RA), Fibromyalgia, Osteoporosis and Gout.
3.1. Osteoarthritis (OA)Obesity directly link with OA this may not simply be due to the increased mechanical stresses on joint tissues resulting from increased weight gain in individuals. Additional soluble factors such as adipokines may also play an important role in the onset of OA in obese patients [20]. OA is also a multifactorial disease that leads to a complete alteration of articular cartilage and other related tissues such as subchondral bone. It is a chronic degenerative disease characterized by loss of articular cartilage, hypertrophy of bone at the margins, subchondral sclerosis and the alterations of biochemical and morphological characteristics of the joint capsule and synovial membrane. The histopathological changes include ulceration, softening, synovial inflammation and focal disintegration of the articular cartilage occurs in the late stage of OA. The typical clinical symptoms includes pain, stiffness etc [21]. It is also known as degenerative arthritis, which mostly affects the hands, feet, spine, hips and knees [21]. It is the second most common rheumatological joint disorder with prevalence of 22% to 39% in India [22-24]. The locomotor disability is most commonly caused in elder and obese people [20].
3.2. Fatness Collision and OsteoarthritisOA is mostly affects weight-bearing joints such as spine, hip, knee and ankle. Mechanical forces during locomotion over the joints are one of the significant causes of OA. The obesity problem is reaching epidemic proportions in the worldwide, and the increase in weight translates to increased mechanical force on the weightbearing joints. It has become one of the leading causes of disability.
BMI is the common parameter used for obesity diagnostics and is calculated as weight in kilograms divided by height in meters squared (kg/m2) [25-27] and it has been used to establish the correlation of OA and obesity. Coggon and co-workers carried out a population-based case-control study in England in 3 different health districts. In which BMI interacted with other significant risk factors, such as previous meniscectomy, previous knee injury, and presence of Heberden nodes. When these are plotted on a graph, an increase in weight created an exponential rise in OA. In this report authors concluded that the patterns of interaction between the risk factors were similar in both sexes, but the risk associated is higher in women than in men with obesity [25].
In another similar study, Cooper and his co-workers [28] concluded that the obesity and hip injury are important risk factors for OA that might be accountable to primary prevention. Manninen and co-workers [29], reviewed the social security registry of Finland and found that the relative risk was highest for bilateral knee OA, and there is positive association between relative body weight and OA similar in men and women. These studies showed that the risk for knee OA increased by 36% for every 2 units of BMI (5 kg) of weight gain [28,29]. It has also been demonstrated that obesity and OA is associated modest at other sites such as the hip, hand and patellofemoral joint, it suggest that both the metabolic and mechanical factors may be responsible for the link between obesity and OA [30-42].
A study on ambulatory loads in overweight and obese subjects indicated that cartilage thickness at the knee joint responds to loading during gait in a similar manner to OA patients. These findings suggest the possibility that increased weight initiates a pathway of cartilage degeneration prior to the emergence of OA symptoms [43]. In a controlled study on twins, showed that increase in each kilogram body weight was associated with increased risk of radiographic symptoms of OA at the knee and carpometacarpal joint [44]. The strong link between high BMI and knee OA was confirmed in another twin study and this link was found not likely to be mediated by shared genetic factors [45]. Obese patients with knee OA have more joint space narrowing in the medial and lateral tibio-femoral compartments than non-obese patients [46].
Obesity is also an important risk factor for the progression of knee OA [47] and has long-term detrimental effects on the knee joint [48]. The role of mechanical factors, specifically malalignment studied mediating in knee OA severity or progression [49]. Although the strong association between knee OA and obesity has been demonstrated, the factors underlying the mechanistic effects have not been elucidated. Age, serum lipids, serum uric acid, blood glucose or diabetes, body fat distribution, blood pressure, smoking, chondrocalcinosis, hysterectomy or estrogen replacement therapy have not been found to affect the obesity and OA relationship [49,50]. However, being overweight is associated with increase in cartilage turnover biomarkers. Cartilage oligomeric matrix protein and collagen type 2 degradation products were increased in individuals with high BMI [51,52].
The association between knee structural alteration and BMI was evaluated in a cross-sectional study including 372 healthy subjects [53]. This study shows that increasing BMI may induce cartilage defects even in those with no radiographic OA, and reasons behind this are completely unknown. Authors of this study proposed that a greater BMI can induce larger knee subchondral bone size or that knee subchondral bone may respond to higher loads by expansion of the joint surface area [53].
3.3. Association of Obesity and Rheumatoid ArthritisRheumatoid arthritis (RA) is a chronic, inflammatory autoimmune disease that causes the immune system to attack the joints. It is a disabling and painful inflammatory condition, which can lead to loss of mobility due to pain and joint destruction. In this condition, commonly small joints are affected, but larger joints are also affected [54]. The risk of RA is higher in women between 40 and 50 years of age, and later age in men [55]. The disease is symmetric, especially as it progresses, and favors the interphalangeal joints of the hands and feet, such as the proximal interphalangeal, metacarpophalangeal, and metatarsophalangeal joints, as well as the wrist and ankle. Joint swelling, deformity, pain, stiffness, and weakness are classic symptoms. Other includes tenderness, synovial thickening, effusion, erythema, and decreased range of motion, ankylosis, and subluxation [56]. RA is common inflammatory arthropathy worldwide and affects up to 0.75% of the Indian population [57-59]. Obesity and RA have been tightly correlated in various studies [60-62].
3.4. Obesity Induced FibromyalgiaFibromyalgia is a medical condition that appears to involve disordered afferent processing which is associated with multiple symptoms like chronic widespread pain, fatigue, sleep disturbances, and cognitive alterations. The core symptoms seen in individuals with fibromyalgia are multifocal pain, fatigue severe enough to limit daily activities, sleep disturbances, cognitive or memory problems, and, in many cases, psychological distress [64,65]. These symptoms and syndromes occur approximately 1.5 - 2 times more commonly in women than men. The sex difference appears more apparent in clinical samples than in population-based samples [66,67].
A number of risk factors are associated with this condition and obesity plays a key role in fibromyalgia’s pathology [68]. In a pilot study of overweight and obese women with fibromyalgia, the relationship between BMI and fibromyalgia symptoms were assessed after a 20- week behavioral weight loss treatment [69]. Participants lost, on average, 4.4% of their initial weight, and weight loss predicted a reduction in fibromyalgia symptoms, pain interference, body satisfaction and quality of life. In a study of obese subjects undergoing bariatric surgery, there was a significant reduction in fibromyalgia syndrome at follow-up 6 - 12 months later [70].
3.5. Impact of Obesity on OsteoporosisOsteoporosis is characterized by low bone mass and microarchitectural deterioration of bone tissue. Osteoporosis is a reduction in the quantity of bone or atrophy of skeletal tissue; an age-related disorder characterized by decreased bone mass and loss of normal skeletal microarchitecture, leading to increased susceptibility to fractures. About 3 million people have osteoporosis in the UK, causing approximately 230,000 fractures each year, according to the National Health Service (NHS). Osteoporosis is a public health threat for an estimated 44 million people in the USA, 55% of people aged 50 or over, says the National Osteoporosis Foundation (NOF). The NOF says that 10 million people currently have osteoporosis, while 34 million are thought to have low bone mass; which places them at significantly increased risk for the condition. At a given age, bone mass results from the amount of bone acquired during growth, i.e. the peak bone mass minus the age-related bone loss which particularly accelerates after menopause [71]. The rate and magnitude of bone mass gain during the pubertal years and of bone loss in later life may markedly differ from one skeletal site to another, as well as from one individual to another. Bone mass gain is mainly related to increases in bone size that is in bone external dimensions, with minimal changes in bone microarchitecture [72].
A number of studies have demonstrated that body weight is closely correlated with bone mineral density (BMD) [73-75]. In cross-sectional studies, a 10 kg increase in body weight is associated with approximately a 1% increase in BMD. This relationship has been demonstrated for both women and men and across cultures but the effect of weight on BMD appears to be stronger in women than in men, [76-78] and more in postmenopausal than premenopausal women [79,80]. Several mechanisms have been proposed to explain the effect of weight on bone density. Firstly, it could be due to the amount of adipose tissue, which is the major site of conversion of androgens to estrogen in both elderly men and women. If estrogen has a greater role in preservation of bone mass in women than men, this may explain why the effect of weight is greater in women than men. This may also explain why shortly after menopause, obese women do not lose bone as rapidly as their non-obese counterparts [64, 65]. A second mechanism relates to the increased mechanical load that heavier individuals place on weightbearing bones. This is supported by some data suggesting that body size is a better determinant in weight bearing rather than non-weight bearing sites [78]. Another study showed that overweight postmenopausal women may be more susceptible to bone loss with weight reduction. Weight loss correlated with BMD loss at the trochanter but not at the femoral neck in the group receiving normal calcium intake daily compared to high calcium intake [81]. Weight loss due to caloric restriction appears to induce rapid bone loss at clinically important sites of fracture, unlike exercise-induced weight loss [82]. In addition, the rapid increase in obesity has led to an escalation in the uptake of surgical techniques to control weight. Procedures that involve duodenal bypassing place individuals at risk for osteoporosis as this is the primary site for calcium absorption [83-85].
3.6. Obesity and Inflammatory ArthritisGout is an inflammatory arthritis triggered by the crystallization of uric acid within the joints and is often associated with hyperuricemia. Acute gout is typically intermittent, constituting one of the most painful conditions experienced by humans. In addition to the morbidity that is attributable to gout itself, the disease is associated with such conditions as the insulin resistance, hypertension, nephropathy, and disorders associated with increased cell turnover [86,87]. The overall disease burden of gout remains substantial and may be increasing. The prevalence of self-reported, physician-diagnosed gout in the Third National Health and Nutrition Examination Survey was found to be greater than 2% in men older than 30 years of age and in women older than 50 years of age [88]. The prevalence increased with increasing age and reached 9% in men and 6% in women older than 80 years of age [89]. Dietary and lifestyle trends and the increasing prevalence of obesity and the metabolic syndrome may explain the increasing incidence of gout.
Gout is the most common form of crystal-induced arthritis and in the United States affects more than 1% of adults [90]. Obesity is a well-known modifiable risk factor in the pathogenesis of gout and serum uric acid is positively associated with BMI [91]. The size of the visceral fat area is the strongest contributor to elevated serum uric acid concentration, decreased uric acid clearance and increased urinary uric acid/creatinine ratio [92]. Although, weight loss is advocated in the overall management of gout, however no study has assessed the effect of weight reduction on uric acid levels or attacks of gout.
3.7. Diabetes and ArthritisDiabetes mellitus (DM) is a chronic disease and has become one of the main threats to human health in recent decades. Diabetes worldwide was estimated at between 151 million and 171 million in the year 2000 and, it is estimated that this number will triple by 2050. Type 1 diabetes is characterized by beta-cell failure, partly due to autoimmune destruction [93] and Type 2 diabetes arises as a result of beta-cell failure combined with associated insulin resistance [94]. In type 2 diabetes, increased hepatic glucose production is considered to play a key role in fasting, as well as postprandial hyperglycemia, and increased gluconeogenesis seems to be needed [95, 96]. Uncontrolled diabetes with increased blood glucose is strongly correlated to causing long-term microvascular and macrovascular complications, such as nephropathy, neuropathy, retinopathy, muscular dystrophy and atherosclerosis [97-101]. There are various anti-diabetic compounds are documented in management of diseases and its complications [102], but long term consumption of these also poses other health threats.
Physical activity is key component of DM and arthritis management [103]. Arthritis which is a barrier to physical activity [104], is the most common cause of disability [105]. DM and arthritis each produce large burdens on world medical budget [106]; they also share some risk factors including age and obesity [107]. The mechanism of this comorbidity remain uncertain; these co-occurring conditions have been associated with a significant reduction in quality of life and increased risk for other severe complications [108]. Understanding the extent to which arthritis produces activity limitation among adults with DM will help raise awareness of the conjoint burden of these two diseases as well as the need of efforts to promote the benefits of physical activity in managing DM and arthritis. A recent most study in USA among adults with DM, the unadjusted prevalence of arthritis was 48.1% (9.6 million) and 55.0% (5.3 million), respectively. After adjusting for other characteristics, the prevalence ratios of arthritis and of arthritis-attributable activity limitation (AAAL) among arthritic adults with versus without DM (95% CI) were 1.44 (1.35 - 1.52) and 1.21 (1.15 - 1.28), respectively.
The Centers for Disease Control and Prevention estimate that >26% of adults over 65 have DM, and noted that diabetes is a key mortality predictor in patients with RA [109,110]. Both RA and diabetes increase the risk of arthritis. The prevalence of arthritis increased with age and BMI and was higher for women, non-Hispanic whites, and inactive adults compared with their counterparts both among adults with and without DM. Among US adults with diagnosed DM, nearly half also have diagnosed arthritis; moreover, more than half of those with both diseases had AAAL. Arthritis can be a barrier to physical activity among adults with diagnosed DM [111].
From various arthritic and rheumatological manifestations, shoulder hand syndrome (SHS), diabetic hand syndrome (DHS), diffuse idiopathic skeletal hyperostosis (DISH) and neuroarthropathy are characteristically associated with DM. Rheumatological diseases are now common, which have an increased prevalence in the diabetic population [112]. All these have a severe clinical course in the diabetic population [113]. There are various reports available in literature [114] regarding rheumatological manifestations in diabetic patients.
The association in between diabetes and frozen shoulder is well documented. An incidence of frozen shoulder is reported by Bridgmen was 11% among diabetic patients. DHS is also known as diabetic cheiroarthropathy or syndrome of limited joint mobility. It was first reported by Jung et al. [115,116] in adults with diabetes and Grgic et al. [117] in paediatric diabetics. Most of the studies suggest a prevalence of about 35% [118,119]. SHS is a special feature in diabetes. The most common cause is trauma apart from other conditions like diabetes, cerebrovascular accident, post-myocardial infarction, barbiturates etc. Association of SHS with diabetes has been reported by Steinbrocker and Argyros [120,121]. Osteoarthritis and diabetes have a positive correlation. Crisp and Heathcoate reported higher incidence in young and middle aged diabetics. Moreover, joint damage starts at an earlier age and is much more severe [122]. DISH, especially of spine, frontalis interna and calcification of the pelvic ligaments were found to be increased in Type 2 DM. In the study by Holt, it was 25% amongst 428 diabetic patients [123,124].
In a study using a large administrative database, subjects with RA were found to have a 50% increase in the risk of DM, even after controlling for glucocorticoid use [125]. These findings relate with earlier administrative database study that found a 40% increase in DM associated with RA [126]. Other studies also found an increased prevalence of DM in RA [126,127]. Finally, a population-based study also found an increase in the risk of DM associated with RA [128]. One study examined DM in RA and found a strong relationship with DM overall, but this was only significant for type 1 DM and not type 2 DM [129-131].
3.8. Diabetes with OsteoporosisType 1 diabetes is linked to low bone density and typically occurs at early age resulting the bone mass is still increasing. Insulin, which is deficient in type 1 diabetes patients, may promote bone growth, size, shape and strength. Diabetes type 1 subjects achieve lower peak bone mass with maximum strength and density which indirectly increases the risk of osteoporosis. Mostly people with type 1 diabetes also have celiac disease symptoms associated with reduced bone mass.
Diabetes prevalence increases sharply with age, and it is projected that by the year 2025, the majority of persons with diabetes will be aged 65 years or older [132, 133]. Although diabetes is often accompanied by vascular and neuropathic comorbidities [134], the threats of physical disability, loss of independence, and diminished quality of life may ultimately be the greatest concern this disease and its associated many complications. Crosssectional data from nationally representative surveys show that 50% of older people with diabetes report difficulty performing daily physical tasks, such as climbing stairs, but few prospective studies have examined the specific impact of diabetes on incident disability or how it may act through its comorbidities [135-137]. Additionally, no prospective studies have assessed the predictors of disability among women with diabetes.
The relationship between diabetes and disability is likely due to multiple factors, because diabetes is related to numerous vascular and neuropathic complications that could conceivably affect functional status [138-143]. The potential role of insulin resistance as a cardiovascular risk factor in patients with inflammatory arthritis has been examined by Svenson, et al., who reported impaired glucose handling in a sample of RA patients compared to controls [144]. These investigators also found evidence of an inverse relationship between insulin sensitivity and acute phase markers in RA. More recently, Dessein, et al. reported significantly higher levels of insulin resistance in patients with inflammatory arthritis compared with controls, and an association between high CRP concentrations and insulin resistance [145,146]. Glucocorticoids, which are commonly used in RA therapy, would also be expected to contribute to insulin resistance [147]. Given that chronic systemic inflammation has been associated with both insulin resistance and type 2 DM, the question arises whether the prevalence of DM is increased in patients with RA. Although no studies to date have directly addressed this question, it has been indirectly examined in some of the studies addressing cardiovascular risk in RA. The results of these studies have been conflicting. Han, et al., using a clinic-based population, found a significantly higher prevalence of type 2 DM in RA patients compared with matched controls [148]. However, contrasting findings were reported from 2 large cohort studies. Solomon and colleagues did not find evidence of an association between RA and DM in a prospective cohort of women [149]. Although delRincon and colleagues noted a significantly higher frequency of diabetes in a cohort of patients with RA compared with that in a population-based cohort of persons without RA, this difference disappeared when the samples were stratified for age [150].
Simard and Mittleman’s population-based study is the first to directly address the question of an association between prevalent RA and DM [151]. These investigators used population-based data collected as part of the National Health and Nutrition Examination Survey (NHANES) III, which included 5302 study subjects aged > 60 years. A total of 144 of these subjects fulfilled criteria for RA, of whom 24 had prevalent diabetes. After controlling for a number of potential confounding factors, including demographic factors, body mass index, physical inactivity, and glucocorticoid prescription, a significant association between RA and DM was not found. These findings must, however, be interpreted in light of the limitations of this study. In particular, the numbers of subjects with RA and DM are very small. This is reflected in the wide confidence intervals of the odds ratios, and suggests that the study may not have adequate power to pick up a moderate association between these 2 conditions. It is worth noting in this context that the adjusted odds ratios for DM in the subset of RA subjects not currently taking glucocorticoids and fasting for at least 8 hours prior to blood draw ranged from 1.29 to 1.57, although again, these findings were not statistically significant.
As an additional concern, included subjects with RA had very mild disease. Only 10% of RA cases were taking disease-modifying drugs, and mean CRP level was only 1.04 mg/dl. Further, the proportion of patients with positive rheumatoid factor was smaller than that seen in other population-based studies of RA [152,153]. Even given the community based setting of this study, these results are surprising and suggest the possibility that patients in the community with more severe RA did not participate in NHANES due to disease-related disability. This would mean the sample of subjects with RA in this study is not representative of all patients with RA. Because DM might be expected to occur more often in patients with more severe RA, who have higher levels of inflammation, the noted prevalence of DM in these patients may be an underestimation. Other factors that may have led to dilution of a true association between RA and DM include the cross-sectional design of the data used in this study. If patients with both RA and DM in the community had increased mortality, the number of survivors in this group would be lower, thus leading to underestimation of the concurrence of these 2 conditions. Further, due to missing data on fasting glucose in a large number of study participants, the prevalence of diabetes could have been underestimated due to asymptomatic patients with type 2 DM not having been included. Finally, the criteria used for definition of RA could have allowed inclusion of patients with other forms of inflammatory arthritis, thus diluting an association between RA and DM. Given the limitations outlined above, an association between RA and DM has not yet been ruled out, despite the lack of a significant association noted in this study. Rather, these findings point to the need for further investigation of this interesting question. Future studies would ideally be prospective, use predefined criteria for diagnosis of both RA and DM, and include larger numbers than in the current study.
The study reported by Simard and Mittleman, along with most recent studies examining the association between RA and DM, have concentrated on type 2 DM. This is of particular interest at present due to the association of this condition with systemic inflammation. There are also, however, reasons for speculation about a possible association between type 1 DM and RA. These include evidence of familial clustering of autoimmune diseases, including RA and type 1 DM, and the common association of the HLA-DR4 allele with both DM and RA [154]. One study found that 13% of 295 RA patients had a first-degree relative with type 1 diabetes [154]. However, another study that examined a cohort of hospitalized RA patients found a prevalence of type 1 DM in the RA cohort similar to that in the general population [154]. Simard and Mittleman do not specify whether they included both type 1 and 2 DM, but given that all patients included in the study were over 60 years of age, it is likely that the majority of patients included in this study had type 2 DM. Chronic systemic inflammation has been clearly shown to predispose to premature atherosclerosis and cardiovascular risk in patients with RA. Chronic inflammation also appears to predispose to development of both insulin resistance and DM. The important question remains whether there is an increased prevalence of DM in patients with RA. Ideally, largescale, prospective studies are needed to gain a clearer picture of the true prevalence of DM in RA patients in the community.
